Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Study reveals HCT as effective treatment for NHL patients regardless of age

Results from a retrospective study of 1,629 patients with non-Hodgkin lymphoma showed that survival at 4 years following allogeneic hematopoietic cell transplantation for patients age 65 years and older is comparable to patients age 55 to 64 years.

21 Feb 2018

Moffitt study identifies new drug target that may reduce GVHD risk

Stem cell transplants can cure patients with high-risk leukemia or lymphoma. Graft-versus-host disease is a potentially life-threatening side effect that occurs when the donor's immune cells attack the recipient's normal tissues.

5 Feb 2018

Scientists develop software that predicts leukemia-specific immune targets

University of North Carolina Lineberger Comprehensive Cancer Center scientists have developed a software program that can accurately predict which tumor-specific markers will show up on the surface of leukemia cells in patients who have received stem cell transplants.

11 Dec 2017

Drug improves disease-free, overall survival after hematopoietic stem cell transplants

Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.

11 Dec 2017

Breakthrough research brings new procedure closer to helping patients with blood cancer

A new procedure that can prevent the potentially lethal side effects of stem cell transplants is a step closer to helping more patients with blood cancers after a breakthrough in understanding of the key mechanism that makes it work.

17 Nov 2017

Monoclonal antibody effectively blocks development of graft-versus-host disease, research shows

Newly published research provides preclinical proof-of-concept for the ability of PRO 140, a humanized anti-CCR5 monoclonal antibody under development by CytoDyn Inc., to effectively block the development of graft-versus-host disease (GvHD), a potentially lethal complication of bone marrow stem cell (BMSC) transplantation.

14 Nov 2017

Scientists develop physiological approach to restore gut’s ecosystem in various diseases

The trillions of microbes living in a mammal's intestine play an important role in the host's metabolism and immunity. The composition of microbiota is maintained by antimicrobial proteins secreted from intestinal cells.

24 Oct 2017

Gene therapy effectively stabilizes progression of cerebral adrenoleukodystrophy, trial reveals

In a recent clinical trial, a gene therapy to treat cerebral adrenoleukodystrophy (CALD) -- a neurodegenerative disease that typically claims young boys' lives within 10 years of diagnosis -- effectively stabilized the disease's progression in 88 percent of patients, researchers from the Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Massachusetts General Hospital report today.

4 Oct 2017

FDA gives its nod to new drug Imbruvica (Ibrutinib) for chronic Graft versus Host Disease

The U.S. Food and Drug Administration (FDA) yesterday in a press release informed about the approval of Imbruvica (ibrutinib) for the treatment of adult patients with chronic graft versus host disease (cGVHD) who have previously failed with one or more treatment. This is the first drug that the FDA has given its approval to in this disease condition.

2 Aug 2017

Seattle Children’s opens first clinical trial to study IBD and GVHD in pediatric patients

In an effort to find new strategies to personalize treatment for pediatric patients, Seattle Children's has opened the first clinical trial applying next-generation T-cell receptor sequencing and single-cell gene expression analysis to better understand how the immune system drives both inflammatory bowel disease in pediatric autoimmunity patients and graft-versus host disease in pediatric bone marrow transplant patients.

From 10x Genomics, Inc. 23 May 2017

Researchers develop new approach to protect stem cell recipients from graft-versus-host disease

Stem cell transplants can save lives, for example in patients with leukemia. However, these treatments are not free of risks. One complication that may occur is graft-versus-host disease (GVHD), basically donor-derived immune cells attacking the recipient’s body.

21 Apr 2017

Researchers find new way to prevent graft-versus-host disease after stem cell transplants

Through experimental work, an international team of researchers led by City of Hope's Defu Zeng, professor of diabetes immunology and hematopoietic cell transplantation, believe they may have found a way to prevent graft-versus-host disease after stem cell transplants while retaining the transplants' positive effects on fighting leukemia and lymphoma.

18 Apr 2017

Hematologist-oncologist to lead bone marrow transplantation program for treating blood-borne cancers

Hematologist-oncologist Ahmad Samer Al-Homsi MD, MBA, will lead a new bone marrow transplantation program at NYU Langone's Perlmutter Cancer Center for treating blood-borne cancers, including leukemia, lymphoma and multiple myeloma, and potentially utilize transplantation as an adjunct to immunotherapy for solid tumors.

10 Apr 2017

Novel antiviral drug can protect transplant patients against CMV infections

In a significant advance in improving the safety of donor stem cell transplants, a major clinical trial led by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital has shown that a novel agent can protect against the most common viral infection that patients face after transplantation.

24 Feb 2017

New ‘MAGIC algorithm’ can predict transplant patient’s risk of developing graft-versus-host disease

Researchers at Mount Sinai Health System have discovered a way to predict whether blood cancer patients who received a bone marrow transplant will develop graft-versus-host disease, a common and often lethal complication, according to a study published in JCI Insight.

9 Feb 2017

Research offers new clues to prolong lifespan of the body's disease-fighting NK cells

A team of researchers from Australia and France have uncovered new insights into how to prolong the lifespan of the body's disease-fighting natural killer (NK) cells.

17 Jan 2017

Novel treatment can effectively inhibit development of GVHD in mice, study shows

Graft-versus-host-disease (GVHD) is the leading cause of non-relapse associated death in patients who receive stem cell transplants.

12 Jan 2017

Mount Sinai awarded $10 million grant to explore cellular, molecular mechanisms of GVHD

Researchers from the Icahn School of Medicine at Mount Sinai have been awarded a $10 million from the National Cancer Institute to explore the cellular and molecular mechanisms of acute graft-versus-host disease (GVHD), a common side effect that occurs after allogeneic bone marrow transplantation (BMT), and to develop novel therapeutic strategies for BMT patients with cancer that begin in the cells of blood-forming tissue or hematologic malignancies.

13 Oct 2016

German scientists develop new approach to prevent GvHD after bone marrow transplants

Scientists in Germany have developed a new approach that may prevent leukemia and lymphoma patients from developing graft-versus-host disease (GvHD) after therapeutic bone marrow transplants.

16 Aug 2016

Umbilical CBT more effective than MUD bone marrow transplants for leukemia patients

A University of Colorado Cancer Center study compared outcomes of leukemia patients receiving bone marrow transplants from 2009-2014, finding that three years post transplant, the incidence of severe chronic graft-versus-host disease was 44 percent in patients who had received transplants from matched, unrelated donors (MUD) and 8 percent in patients who had received umbilical cord blood transplants (CBT).

27 Jul 2016

Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Study reveals HCT as effective treatment for NHL patients regardless of age

Moffitt study identifies new drug target that may reduce GVHD risk

Scientists develop software that predicts leukemia-specific immune targets

Drug improves disease-free, overall survival after hematopoietic stem cell transplants

Breakthrough research brings new procedure closer to helping patients with blood cancer

Monoclonal antibody effectively blocks development of graft-versus-host disease, research shows

Scientists develop physiological approach to restore gut’s ecosystem in various diseases

Gene therapy effectively stabilizes progression of cerebral adrenoleukodystrophy, trial reveals

FDA gives its nod to new drug Imbruvica (Ibrutinib) for chronic Graft versus Host Disease

Seattle Children’s opens first clinical trial to study IBD and GVHD in pediatric patients

Researchers develop new approach to protect stem cell recipients from graft-versus-host disease

Researchers find new way to prevent graft-versus-host disease after stem cell transplants

Hematologist-oncologist to lead bone marrow transplantation program for treating blood-borne cancers

Novel antiviral drug can protect transplant patients against CMV infections

New ‘MAGIC algorithm’ can predict transplant patient’s risk of developing graft-versus-host disease

Research offers new clues to prolong lifespan of the body's disease-fighting NK cells

Novel treatment can effectively inhibit development of GVHD in mice, study shows

Mount Sinai awarded $10 million grant to explore cellular, molecular mechanisms of GVHD

German scientists develop new approach to prevent GvHD after bone marrow transplants

Umbilical CBT more effective than MUD bone marrow transplants for leukemia patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in